We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
HHS Secretary Tommy Thompson must turn over all cost estimates associated with the new prescription drug benefit added to the Medicare program by Feb. 17, House Democratic leaders demanded last week.
A House Republican leader on government healthcare spending issues is eyeing lower Medicaid drug reimbursements and improved collection of manufacturers' rebates as ways to rein in the program's spending on pharmaceuticals.
A House investigation is focusing on allegations that drugmakers have suppressed clinical trial data that shows increased risk of suicide in children who are treated with anti-depressants.
House Democratic leaders are demanding HHS Secretary Tommy Thompson provide to them by Feb. 17 all cost estimates associated with the new prescription drug benefit added to the Medicare program.
The press secretary for Republican Rep. Billy Tauzin reacted with scorn to a public advocacy group’s request that the Louisiana congressman be investigated for ethics violations in light of reports that he has been offered a job by a drug industry trade association.
The House passed a bill last week that would put an 18-month moratorium on the device branding provision in the Medical Device User Fee and Modernization Act (MDUFAMA).
The FDA has been asked by a high-ranking House Democrat to explain why the enforcement of regulations barring false and misleading drug advertisements has declined, despite promises from agency Commissioner Mark McClellan that actions would increase.
The House Energy and Commerce Committee wants to know more about the relationship between drugmakers’ pricing practices and Medicaid drug reimbursement rates and asked five major retail pharmacy chains to turn over their Medicaid pricing and rebate records.
The House Energy and Commerce Committee continued to expand its investigation into pharma distribution issues earlier in the month, concerned that the FDA is not being informed of adverse events relating to patients who get their Rx drugs online.